Detection method of levamlodipine besylate tablet related substances
Through the optimization conditions of high-performance liquid chromatography, including specific chromatographic columns, mobile phases and detection wavelengths, the problem of incomplete separation of impurities in the detection of levamlodipine benzenesulfonate tablets in the prior art is solved, and the detection sensitivity and The degree of separation ensures the control of drug quality.
Patent Information
- Application Number
- CN202311223357.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-21
- Publication Date
- 2024-12-03
AI Technical Summary
The existing substance detection methods for levamlodipine benzenesulfonate tablets cannot effectively separate unknown impurities and known impurities, and the sensitivity and peak shape are not good enough, which affects drug quality control.
High performance liquid chromatography is used to optimize detection conditions to improve the resolution and peaking of impurities through specific chromatographic columns, mobile phases and detection wavelength combinations, including the use of octadecylsilane-bonded silica gel columns, 0.7% Tri-B The mobile phase combination of amine solution and methanol-acetonitrile was tested with a detection wavelength of 237 nm, a flow rate of 1.0 ml/min, a column temperature of 25°C, and a injection volume of 20 μl.
Good separation and peak shape between each impurity is achieved, the detection sensitivity is improved, the baseline fluctuations are gentle, and the problem of incomplete separation of impurities in the original method is solved.
Smart Images

Figure CN119064485A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug detection and relates to a method for detecting related substances of levamlodipine besylate tablets. Background Art
[0002] Levoamlodipine besylate belongs to the second generation of dihydropyridine long-acting calcium antagonists (or ion blockers), which can block the calcium ion channels (slow channels) of the myocardial and vascular smooth muscle cell membranes, block calcium ions from crossing the membranes and entering the myocardial and vascular smooth muscle cells, directly relax the vascular smooth muscle, and produce an antihypertensive effect (slow and lasting effect). The mechanism of action of this drug in relieving angina pectoris has not been fully determined, but it may reduce myocardial ischemia and relieve angina pectoris through the following effects. Dilate peripheral arterioles and reduce peripheral vascular resistance (afterload), thereby reducing myocardial energy consumption and oxygen demand. Dilate the coronary arteries and coronary arterioles in normal and ischemic areas, relieve coronary artery spasm, and increase myocardial oxygen supply.
[0003] The control of related substances of products is crucial to product quality control. Among the current detection methods for related substances of levamlodipine besylate tablets, only the Chinese Pharmacopoeia includes the detection method for related substances of levamlodipine besylate tablets. However, after the inventors reproduced the method, they found that the pharmacopoeia method cannot effectively separate unknown impurities from all known impurities, and has the phenomenon of poor sensitivity and peak shape. In order to ensure the quality of the preparation during research, production, storage, sales and use, and ensure the safety and effectiveness of the drug, it is urgent to provide a detection method with high sensitivity and good separation between impurities. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a method for detecting related substances of levamlodipine besylate tablets. The chromatographic conditions of the present invention are compared with the standard chromatographic conditions provided in the Chinese Pharmacopoeia. Both the peak shape and separation degree of impurities are improved compared with the original chromatographic conditions.
[0005] There are 8 known impurities that may be contained in the final product of levamlodipine besylate tablets:
[0006]
[0007]
[0008] The technical solution provided by the present invention is as follows:
[0009] A method for detecting related substances of levamlodipine besylate tablets comprises the following steps:
[0010] High performance liquid chromatography was used to quantitatively detect the related substances in levamlodipine besylate tablets;
[0011] HPLC conditions included:
[0012] Chromatographic column: Octadecylsilane bonded silica gel as filler (Ultimate LP-C18 column, 4.6 mm × 250 mm, 5 μm or a chromatographic column with equivalent performance);
[0013] Mobile phase A: 0.7% triethylamine solution (take 7.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH value to 3.0 ± 0.1 with phosphoric acid);
[0014] Mobile phase B: methanol-acetonitrile (70:30);
[0015] Flow rate: 1.0ml / min;
[0016] Detection wavelength: 237nm;
[0017] The injection volume was 20 μl;
[0018] Diluent: Take 200ml of mobile phase A and 800ml of mobile phase B and mix well.
[0019] Further, the elution procedure is as follows:
[0020]
[0021] Furthermore, the related substances are impurity A, impurity B, impurity D, impurity E, impurity F, impurity G, impurity H, and impurity I.
[0022] Further, the test solution and the system suitability solution are respectively injected into a liquid chromatograph to record the chromatogram. The preparation method of the test solution and the system suitability solution is as follows:
[0023] Take levamlodipine besylate reference substance, impurity A, impurity B, impurity D, impurity E, impurity F, impurity G, impurity H, and impurity I reference substances, add methanol to dissolve by ultrasonication, and then dilute to prepare a solution containing approximately 1 mg of levamlodipine, 2 μg of impurity A, 2 μg of impurity B, 5 μg of impurity D, 2 μg of impurity E, 2 μg of impurity F, 2 μg of impurity G, 2 μg of impurity H, and 2 μg of impurity I per 1 ml; as the system suitability solution;
[0024] Take 25 mg levoamlodipine besylate tablets containing 25 mg levoamlodipine, place them in a 25 ml volumetric flask, add solvent, ultrasonically treat for 30 minutes, cool to room temperature, dilute with solvent, shake well, filter, and take the filtrate as the test solution.
[0025] Furthermore, the test solution was diluted 500 times with a diluent to serve as a 0.2% self-control solution.
[0026] Furthermore, the color spectrum is recorded, and the content of individual impurities and total impurities is calculated by self-control method.
[0027] Furthermore, the calculation method of individual impurities and total impurities is:
[0028] Single impurity % = single impurity peak area / control peak area * 0.2%;
[0029] Total impurities % = sum of impurity peak areas / control peak area*0.2%.
[0030] Furthermore, the injection volume was 20 μl.
[0031] Furthermore, the column temperature was 25°C.
[0032] A method for detecting related substances of levamlodipine besylate tablets comprises the following steps:
[0033] (1) Solution preparation:
[0034] Solvent: Mix 200ml of mobile phase A and 800ml of mobile phase B;
[0035] Take appropriate amounts of levamlodipine besylate reference substance, impurity A, impurity B, impurity D, impurity E, impurity F, impurity G, impurity H, and impurity I reference substances, add solvent to dissolve by ultrasonication, and then dilute to prepare a solution containing approximately 1 mg of levamlodipine, 2 μg of impurity A, 2 μg of impurity B, 5 μg of impurity D, 2 μg of impurity E, 2 μg of impurity F, 2 μg of impurity G, 2 μg of impurity H, and 2 μg of impurity I per 1 ml, as the system suitability solution;
[0036] Take 10 tablets of this product, put them in a 25ml volumetric bottle, add an appropriate amount of solvent, and sonicate for 30 minutes to dissolve the amlodipine besylate, cool, dilute to the scale with solvent, shake well, filter, and take the filtrate as the test solution;
[0037] (2) Chromatographic conditions:
[0038] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0039] Chromatographic column: Ultimate LP-C18 column, 4.6 mm × 250 mm, 5 μm;
[0040] Mobile phase A: 0.7% triethylamine solution (take 7.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH value to 3.0 ± 0.1 with phosphoric acid);
[0041] Mobile phase B: methanol-acetonitrile (70:30);
[0042] Flow rate: 1.0ml / min;
[0043] Column temperature: 25°C;
[0044] Detection wavelength: 237nm;
[0045] The injection volume was 20 μl;
[0046] The elution procedure is as follows:
[0047]
[0048] (3) Determination: Take 20 μl of the test solution and system suitability solution respectively and inject them into the liquid chromatograph and record the chromatogram.
[0049] Beneficial Effects
[0050] The present invention provides for the first time an optimized method for detecting related substances of levamlodipine besylate tablets. The chromatographic conditions provided have good separation between the impurities and the main peak and good peak shape, and the baseline fluctuation is gentle. Both the peak shape and separation of the impurities are improved compared with the original chromatographic conditions. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 A chromatogram of the solution for the test method-system suitability;
[0052] Figure 2 It is the solution chromatogram of system suitability under the two chromatographic conditions of the detection method;
[0053] Figure 3 It is the solution chromatogram of system suitability under the three chromatographic conditions of the detection method;
[0054] Figure 4 It is the chromatogram of high temperature sample test of system suitability solution under the three chromatographic conditions of the test method;
[0055] Figure 5 The solution chromatogram of the system suitability under the chromatographic conditions of the detection method IV;
[0056] Figure 6 The chromatogram of the solution for system suitability under the five chromatographic conditions of the test method;
[0057] Figure 7 This is the solution chromatogram of system suitability under the five chromatographic conditions of the detection method. DETAILED DESCRIPTION
[0058] Example 1
[0059] Detection method 1 for related substances in amlodipine besylate tablets:
[0060] (1) Solution preparation:
[0061] Solvent: mobile phase;
[0062] Stock solution of each impurity: weigh 1 mg of each impurity, place it in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale. (The sample weight of impurity A is 1.182 mg, the sample weight of impurity D is 1.380 mg, the sample weight of impurity E is 1.148 mg, the sample weight of impurity F is 1.149 mg, the sample weight of impurity G is 1.070 mg, the sample weight of impurity H is 1.050 mg, and the sample weight of impurity I is 1.181 mg)
[0063] System suitability solution: System suitability solution: Weigh approximately 10 mg of levamlodipine besylate into a 10 ml volumetric flask, add 0.5 ml of each impurity stock solution, dilute to the scale with the mobile phase and shake well.
[0064] Test solution: Take 8 levamlodipine besylate tablets and place them in a 25 ml volumetric flask, add mobile phase and sonicate for 30 minutes, then centrifuge and take the supernatant.
[0065] (2) Chromatographic conditions:
[0066] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0067] Chromatographic column: Thermo scientific Syncronis C18 4.6*150mm, 5μm;
[0068] Mobile phase: 0.7% triethylamine (pH 3.0): methanol: acetonitrile = 50:35:15;
[0069] Flow rate: 1.0ml / min;
[0070] Column temperature: 25°C;
[0071] Detection wavelength: 237nm;
[0072] The injection volume was 50 μl;
[0073] Elution procedure: isocratic elution;
[0074] (3) Determination: Take 50 μl of blank solution, system suitability solution and test solution respectively and inject them into liquid chromatograph. Record the chromatogram. Typical spectra are shown in Figure 1 .
[0075] (4) Results: Figure 1 It can be seen from the spectrum that after adding 7 impurities and running the method for 2 hours, there are only 5 impurities in the system. This method needs to be optimized by changing from isocratic to gradient elution.
[0076] Example 2
[0077] Method 2 for the detection of related substances in amlodipine besylate tablets:
[0078] (1) Solution preparation: the same as that in Example 1.
[0079] (2) Chromatographic conditions: Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0080] Chromatographic column: Thermo scientific Syncronis C18 4.6*150mm, 5μm;
[0081] Mobile phase A: 0.7% triethylamine solution (take 7.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH value to 3.0 ± 0.1 with phosphoric acid);
[0082] Mobile phase B: methanol-acetonitrile (70:30);
[0083] Flow rate: 1.0ml / min;
[0084] Column temperature: 30°C;
[0085] Detection wavelength: 237nm;
[0086] The injection volume was 50 μl;
[0087] The elution procedure is as follows:
[0088]
[0089] (3) Determination: Take 50 μl of the test solution and system suitability solution respectively and inject them into the liquid chromatograph. Record the chromatogram. Typical spectra are shown in Figure 2 .
[0090] (4) Results: Figure 2 As shown, the impurities in the system suitability solution are well separated, impurity I has unknown peak interference, and the sample solution is well separated. Continue to optimize the gradient to separate the impurities better.
[0091] Example 3
[0092] Detection method 3 for related substances in amlodipine besylate tablets:
[0093] (1) Solution preparation: the same as that in Example 1.
[0094] (2) Chromatographic conditions:
[0095] Chromatographic column: Thermo scientific Syncronis C18 4.6*150mm, 5μm;
[0096] Mobile phase A: 0.7% triethylamine solution (take 7.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH value to 3.0 ± 0.1 with phosphoric acid);
[0097] Mobile phase B: methanol-acetonitrile (70:30);
[0098] Flow rate: 1.0ml / min;
[0099] Column temperature: 40°C;
[0100] Detection wavelength: 237nm;
[0101] The injection volume was 50 μl;
[0102] The elution procedure is as follows:
[0103]
[0104] (3) Determination: Inject the system suitability solution into the liquid chromatograph and record the chromatogram. Typical spectra are shown in Figure 3 .
[0105] (4) Results: Figure 3-Figure 4 As shown in the figure, it can be seen from the spectrum that under the gradient conditions, the separation degree of each impurity is good, but the separation degree of unknown impurities in the method is not enough when testing high-temperature samples.
[0106] Example 4
[0107] Method 4 for the detection of related substances in amlodipine besylate tablets:
[0108] (1) Solution preparation:
[0109] Solvent: Mobile phase A-Mobile phase B (20:80)
[0110] Stock solution of each impurity: weigh 1 mg of each impurity, place it in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale. (The sample weight of impurity A is 1.182 mg, the sample weight of impurity D is 1.380 mg, the sample weight of impurity E is 1.148 mg, the sample weight of impurity F is 1.149 mg, the sample weight of impurity G is 1.070 mg, the sample weight of impurity H is 1.050 mg, the sample weight of impurity I is 1.181 mg, and the sample weight of impurity B is 1.439 mg)
[0111] System suitability solution: Weigh about 10 mg of levamlodipine besylate into a 10 ml volumetric flask, add 0.5 ml of each impurity stock solution, dilute to the scale with solvent and shake well.
[0112] Test solution (high temperature): Take 4 tablets of levamlodipine besylate and place them in a 25ml volumetric bottle, add 2ml of water, place at high temperature of 60℃ for 5 days, add appropriate amount of solvent, ultrasonicate for 30min, and then centrifuge to obtain the supernatant.
[0113] (2) Chromatographic conditions
[0114] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0115] Mobile phase A: 0.7% triethylamine solution (take 7.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH value to 3.0 ± 0.1 with phosphoric acid);
[0116] Mobile phase B: methanol-acetonitrile (70:30);
[0117] Flow rate: 1.0ml / min;
[0118] Column temperature: 25°C;
[0119] Detection wavelength: 237nm;
[0120] The injection volume was 20 μl;
[0121] The elution procedure is as follows:
[0122]
[0123] (3) Determination: Accurately measure the reference substance, test solution and system suitability solution and inject them into the liquid chromatograph respectively, and record the chromatogram. Typical chromatograms are shown in Figure 4 .
[0124] (4) Results: See Figure 5 As shown in the figure, it can be seen from the spectrum that under the gradient condition, the separation degree of unknown impurities and known impurities I in the sample destroyed by high temperature liquid is 1.208, and the separation degree of unknown impurities and impurity D in the sample destroyed by light is 1.315. This method is selected to detect related substances. When this method is used to detect samples later, it is found that some unknown impurities peak after 70 minutes. Continue to optimize the elution gradient.
[0125] Example 5
[0126] Method 5 for the detection of related substances in levamlodipine besylate tablets:
[0127] (1) Solution preparation:
[0128] System suitability solution: same as the solution in Example 4.
[0129] Test solution: Take 10 levamlodipine besylate tablets and place them in a 25 ml volumetric flask, add solvent, ultrasonicate for 30 minutes, and then centrifuge to obtain the supernatant.
[0130] (2) Chromatographic conditions:
[0131] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0132] Mobile phase A: 0.7% triethylamine solution (take 7.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH value to 3.0 ± 0.1 with phosphoric acid);
[0133] Mobile phase B: methanol-acetonitrile (70:30);
[0134] Flow rate: 1.0ml / min;
[0135] Column temperature: 25°C;
[0136] Detection wavelength: 237nm;
[0137] The injection volume was 20 μl;
[0138] The elution procedure is as follows:
[0139]
[0140] (3) Determination: Take the above solutions respectively and inject them into the liquid chromatograph, and record the chromatogram. The typical spectrum is shown in Figure 5 .
[0141] (4) Results: See Figure 6-Figure 7 As shown in the figure, it can be seen from the spectrum that under the gradient conditions, all the unknown substances in the test solution are completely eliminated within 80 minutes, so this method is selected to detect the relevant substances.
[0142] Example 6
[0143] Method 6 for investigating the solvents of related substances in amlodipine besylate tablets:
[0144] (1) Solution preparation:
[0145] Blank solvent (ChP method): mobile phase A-mobile phase B (50:50)
[0146] Blank solvent (self-developed method): mobile phase A-mobile phase B (20:80)
[0147] System suitability solution: same as the solution in Example 4.
[0148] Test solution: Take 10 tablets of this product (equivalent to 25 mg of amlodipine), place them in a 25 ml volumetric flask, prepare two parallel portions, add 20 ml of different solvents, shake to disintegrate the tablets, ultrasonically treat for 30 minutes, cool to room temperature, add solvent to dilute to the scale, shake well, filter, and take the filtrate to obtain the solution.
[0149] (2) Chromatographic conditions: same as in Example 5.
[0150] (3) Determination
[0151] Accurately measure the blank solvent, system suitability solution, and test solution, inject them into the liquid chromatograph, and record the chromatogram. The data is shown in Table 1 below:
[0152] Table 1 Method development for related substances - investigation of test sample solvents
[0153]
[0154] (4) Results: The same known and unknown impurities were detected in the test solutions prepared with different blank solvents, and the proportions of each impurity were consistent. Therefore, the two blank solvents had no effect on the detection of the test product. However, the test solution prepared with the blank solvent (ChP method) would have solid precipitation when placed at room temperature in a light-proof environment, while the test solution prepared with the blank solvent (self-developed method) would not have solid precipitation when placed at room temperature in a light-proof environment. Therefore, the test solution prepared with the blank solvent (self-developed method) was selected.
[0155] Example 7
[0156] Extraction investigation method 7 for related substances of amlodipine besylate tablets:
[0157] (1) Solution preparation:
[0158] Blank solvent: mobile phase A-mobile phase B (20:80)
[0159] System suitability solution: same as the solution in Example 4.
[0160] Test solution: Take 10 tablets of this product (equivalent to 25 mg of amlodipine), put them in a 25 ml volumetric flask, add 20 ml of solvent, shake to disintegrate the tablets, prepare 6 portions in parallel, ultrasonically treat for 15 minutes, 30 minutes, and 45 minutes respectively, cool to room temperature, add solvent to dilute to the scale, shake well, filter, and take the filtrate to obtain.
[0161] (2) Chromatographic conditions: same as in Example 5.
[0162] (3) Determination
[0163] Accurately measure the blank solvent, system suitability solution, and test solution, inject them into the liquid chromatograph, and record the chromatogram. The data is shown in Table 2 below:
[0164] Table 2 Method development for related substances - investigation of sample extraction
[0165]
[0166]
[0167] (4) Results: No unknown impurities were detected in the test solutions. Therefore, the ultrasonic time during the preparation of the test solutions was investigated by comparing the impurities D and F of levoamlodipine. The self-made products (batch 23052601) were treated with ultrasonic time of 15 minutes, 30 minutes, and 45 minutes, respectively. The test results were basically consistent. Therefore, ultrasonic time of 30 minutes was initially selected for the preparation of the test solutions.
[0168] Example 8
[0169] Method 8 for investigating the specificity of related substances in levamlodipine besylate tablets:
[0170] (1) Solution preparation:
[0171] Each impurity stock solution: same as Example 4.
[0172] Impurity A localization solution: Pipette 100 μl of the impurity A stock solution and add 1.5 ml of solvent and mix well.
[0173] Impurity B localization solution: Pipette 100 μl of impurity A stock solution and add 1.5 ml of solvent and mix well.
[0174] Impurity D localization solution: Pipette 100 μl of the impurity D stock solution and add 1.5 ml of solvent and mix well.
[0175] Impurity E localization solution: Pipette 100 μl of the impurity E stock solution and add 1.5 ml of solvent and mix well.
[0176] Impurity F localization solution: Pipette 100 μl of the impurity F stock solution and add 1.5 ml of solvent and mix well.
[0177] Impurity G localization solution: Pipette 100 μl of the impurity G stock solution and add 1.5 ml of solvent and mix well.
[0178] Impurity H localization solution: Pipette 100 μl of the impurity H stock solution and add 1.5 ml of solvent and mix well.
[0179] Impurity I localization solution: Pipette 100 μl of the impurity I stock solution and add 1.5 ml of solvent and mix well.
[0180] Benzenesulfonic acid fixing solution: weigh 11.81 mg of benzenesulfonic acid and place it in a 100 ml volumetric flask, add appropriate amount of solvent, sonicate, cool to room temperature, and adjust to volume.
[0181] Blank solvent: mobile phase A-mobile phase B (20:80)
[0182] System suitability solution: same as the solution in Example 4.
[0183] Blank excipient solution: weigh 387.78 mg of blank excipient and place it in a 25 ml volumetric flask, add appropriate amount of solvent, sonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0184] Test solution: Take 4 levamlodipine besylate tablets and place them in a 25 ml volumetric flask, add appropriate amount of solvent, sonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0185] Undestroyed blank solution: blank solvent.
[0186] Undamaged test solution: Take 4 levamlodipine besylate tablets and put them into a 25 ml volumetric flask, add appropriate amount of solvent, sonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0187] Undamaged raw material solution: Take 13.8 mg of levamlodipine besylate raw material into a 25 ml volumetric flask, add an appropriate amount of solvent, sonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0188] Acid-destroyed test solution: Take 4 levamlodipine besylate tablets into a 25 ml volumetric flask, add 1 ml of 1 M hydrochloric acid solution, let it stand at room temperature for 1 hour, neutralize it with 1 M sodium hydroxide solution, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0189] Acid-destroyed raw material solution: Take 13.8 mg of amlodipine besylate raw material into a 25 ml volumetric flask, add 1 ml of 1M hydrochloric acid solution, let it stand at room temperature for 1 hour, neutralize it with 1M sodium hydroxide solution, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0190] Alkali-destroyed test solution: put 4 levamlodipine besylate tablets into a 25 ml volumetric flask, add 1 ml of 0.1 M sodium hydroxide solution, let it stand at room temperature for 1 hour, neutralize it with 0.1 M hydrochloric acid solution, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0191] Alkali-destroyed raw material solution: Take 13.8 mg of levamlodipine besylate raw material into a 25 ml volumetric flask, add 1 ml of 1M sodium hydroxide solution, let it stand at room temperature for 1 hour, neutralize it with 1M hydrochloric acid solution, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0192] Oxidatively damaged test solution: put 4 levamlodipine besylate tablets into a 25 ml volumetric flask, add 1 ml of 30% hydrogen peroxide, let stand at room temperature for 1 hour, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0193] Oxidatively damaged raw material solution: Take 13.8 mg of amlodipine besylate raw material into a 25 ml volumetric flask, add 1 ml of 30% hydrogen peroxide, leave it at room temperature for 1 hour, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0194] High temperature damaged test sample (solid): put 4 levamlodipine besylate tablets into a 25 ml volumetric flask and place at 60°C for 10 days, add appropriate amount of solvent, sonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0195] Test sample (solution) destroyed by high temperature: put 4 levamlodipine besylate tablets into a 25ml volumetric flask, add 2ml of water, place at 60℃ for 5 days, add appropriate amount of solvent, ultrasonicate for 30min, cool to room temperature, make up to volume, centrifuge at 8000rpm for 10min, and take the supernatant.
[0196] High temperature damaged raw materials (solid): add 13.8 mg of levamlodipine besylate raw material to a 25 ml volumetric flask and place it at 60°C for 10 days, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0197] High temperature destroyed raw materials (solution): put 13.8 mg of levamlodipine besylate raw material into a 25 ml volumetric flask, add 2 ml of water, place at 60°C for 10 days, take out, add appropriate amount of solvent, ultrasonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0198] Light-damaged test sample (solid): Add 4 levamlodipine besylate tablets into a 25 ml volumetric flask, place under light for 10 days, take out, add appropriate amount of solvent, sonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0199] Light-damaged test sample (solution): put 4 levamlodipine besylate tablets into a 25 ml volumetric flask, add 2 ml of water, place under light for 5 days, take out, add appropriate amount of solvent, ultrasonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0200] Light-damaged raw materials (solid): Add 13.8 mg of levamlodipine besylate raw material into a 25 ml volumetric flask, place under light for 10 days, take it out, add appropriate amount of solvent, ultrasonicate for 30 minutes, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 minutes, and take the supernatant.
[0201] Light-damaged raw materials (solution): Add 13.8 mg of levamlodipine besylate raw material to a 25 ml volumetric flask, add 2 ml of water, place under light for 10 days, take out, add appropriate amount of solvent, ultrasonicate for 30 min, cool to room temperature, make up to volume, centrifuge at 8000 rpm for 10 min, and take the supernatant.
[0202] (2) Chromatographic conditions: same as in Example 5.
[0203] (3) Determination
[0204] Accurately measure blank solvent, each impurity location solution, blank excipient solution system suitability solution, test solution, undamaged test solution, acid-damaged test solution, alkali-damaged test solution, high temperature-damaged test solution, light-damaged test solution, and oxidative-damaged test solution and inject them into the liquid chromatograph respectively, and record the chromatogram. The data are shown in Tables 3 and 4 below:
[0205] Table 3: Summary of degradation tests - oxidation, acid and alkali damage
[0206]
[0207]
[0208] Table 4 Summary of degradation tests - high temperature and light damage
[0209]
[0210] (4) Results: Blank solvent, blank excipients and other components in the test sample had no interference with the test. Under various degradation conditions, levamlodipine besylate was unstable under light and high-temperature liquid conditions, but relatively stable under acid, alkali, oxidation and high-temperature solid conditions. This method has good specificity.
[0211] Example 9
[0212] Method 9 for investigating the specificity of related substances in levamlodipine besylate tablets:
[0213] (1) Solution preparation:
[0214] Each impurity stock solution: same as Example 4.
[0215] Blank solvent: mobile phase A-mobile phase B (20:80).
[0216] For test + standard solution: take 8 tablets of levamlodipine besylate and place them in a 50ml volumetric bottle, add appropriate amount of solvent and sonicate for 30min, add 1ml of each impurity mother solution, dilute to the scale with solvent, and shake well.
[0217] (2) Chromatographic conditions: same as in Example 5.
[0218] (3) Determination
[0219] Accurately measure the blank solvent and the test solution, and inject them into the liquid chromatograph at 0h, 4h, 8h, 12h, 16h, 20h, 24h, 28h, 32h, 36h, 40h, 44h, and 48h, respectively, and record the chromatogram. The data are shown in Table 5 below:
[0220]
[0221]
[0222] (4) Results: After the test sample + standard solution was placed for 48 hours, the peak area ratio of the impurity and main component to the 0-hour value met the requirements within 24 hours, indicating that the test sample + standard solution was stable within 24 hours.
[0223] Example 10
[0224] Method 10 for investigating the specificity of related substances in levamlodipine besylate tablets:
[0225] (1) Solution preparation:
[0226] System suitability solution: same as the solution in Example 4.
[0227] (2) Chromatographic conditions: same as in Example 5.
[0228] The parameters are changed as follows:
[0229] Change the initial ratio of the mobile phase, keeping other conditions unchanged:
[0230] ①The initial ratio of organic phase is A:B=52:48; ②The initial ratio of organic phase is A:B=48:52
[0231] Change the column temperature, keeping other conditions unchanged:
[0232] ① Column temperature 23℃; ② Column temperature 27℃
[0233] Change the detection wavelength, other conditions remain unchanged:
[0234] Wavelength 235nm; ② Wavelength 239nm
[0235] Change the flow rate, other conditions remain unchanged:
[0236] ①Flow rate 0.9ml / min; ②Flow rate 1.1ml / min
[0237] Change the pH value of the mobile phase, keeping other conditions unchanged:
[0238] ①pH=2.8; ②pH=3.2
[0239] Replace the column
[0240] (3) Determination
[0241] Accurately measure the blank solvent and system suitability solution, inject them into the liquid chromatograph, and record the chromatogram. The data is shown in Table 6 below:
[0242]
[0243] From the above table data, it can be seen that the column temperature, flow rate, pH value of the mobile phase, wavelength, organic phase ratio of the mobile phase and different chromatographic columns vary slightly, and the separation degree of each impurity is good, indicating that the method of this method is durable.
Claims
1. A method for detecting related substances in levamlodipine besylate tablets, characterized in that: The following steps are involved: High performance liquid chromatography was used to quantitatively detect the related substances in levamlodipine besylate tablets; HPLC conditions included: Chromatographic column: octadecylsilane bonded silica gel as filler; Mobile phase A: 0.7% triethylamine solution; Mobile phase B: methanol-acetonitrile in a volume ratio of 7:3; Flow rate: 1.0ml / min; Detection wavelength: 237nm; Diluent: Mobile phase A-mobile phase B in a volume ratio of 2:
8.
2. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: The elution procedure is as follows:
3. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: The related substances are impurity A: 3-ethyl 5-methyl 4-(2-chlorophenyl)-2-{[2-(1,3-dioxoisoindol-2-yl)ethoxy]methyl}-6-methyl-1,4-dihydropyridine-3,5-dimethyl ester; impurity B: 3-ethyl 5-methyl 4-(2-chlorophenyl)-6-methyl-2-{[2-(2-(methylaminoformyl)benzamido)ethoxy]methyl}-1,4-dihydropyridine-3,5-dimethyl ester; impurity D: 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-3,5-pyridinedicarboxylic acid-5-methyl ester, 3-ethyl ester; impurity E: diethyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl- 1,4-dihydropyridine-3,5-dimethyl ester; Impurity F: dimethyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dimethyl ester; Impurity G: dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dimethyl ester; Impurity H: 2-{[2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridin-2-yl)methoxy)ethyl]carbamoyl}benzoic acid; Impurity I: 5-ethyl-7-methyl-6-(2-chlorophenyl)-8-methyl-3,4,6,7-tetrahydro-2H-1,4-benzoxazine-5,7-dicarboxylic acid.
4. The method for detecting related substances in levamlodipine besylate tablets according to claim 3, characterized in that: Inject the test solution and the system suitability solution into the liquid chromatograph respectively and record the chromatogram. The preparation method of the test solution and the system suitability solution is as follows: Take levamlodipine besylate reference substance, impurity A, impurity B, impurity D, impurity E, impurity F, impurity G, impurity H, and impurity I reference substances, add methanol to dissolve by ultrasonication, and then dilute to prepare a solution containing 1 mg of levamlodipine, 2 μg of impurity A, 2 μg of impurity B, 5 μg of impurity D, 2 μg of impurity E, 2 μg of impurity F, 2 μg of impurity G, 2 μg of impurity H, and 2 μg of impurity I per 1 ml; as the system suitability solution; Take 25 mg levoamlodipine besylate tablets containing 25 mg levoamlodipine, place them in a 25 ml volumetric flask, add solvent, ultrasonically treat for 30 minutes, cool to room temperature, dilute with solvent, shake well, filter, and take the filtrate as the test solution.
5. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: Dilute the test solution 500 times with diluent to prepare a 0.2% self-control solution.
6. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: The mobile phase A was prepared by taking 7.0 ml of triethylamine, diluting it to 1000 ml with water, and adjusting the pH value to 3.0±0.1 with phosphoric acid.
7. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: Record the chromatogram, measure using the self-control method, and calculate the content of individual impurities and total impurities.
8. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: The calculation method for individual impurities and total impurities is: Single impurity % = single impurity peak area / control peak area * 0.2%; Total impurities % = sum of impurity peak areas / control peak area*0.2%.
9. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: The injection volume was 20 μl.
10. The method for detecting related substances in levamlodipine besylate tablets according to claim 1, characterized in that: The column temperature was 25°C.
Citation Information
Cited By
Determination method for irbesartan and levoamlodipine compound tablet related substances
CN120522320A
